期刊
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
卷 2019, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2019/2531493
关键词
-
类别
资金
- Natural Science Foundation of China [21571153]
- Henan Science and Technology Agency [14300510012, 152300410118]
- Key Research Project Funding Program of Higher Educational Institutions of Henan Province [19A310021]
- Innovation Team by the Sanquan College of Xinxiang Medical University [SQTD201703, SQTD201802]
Epithelial-mesenchymal transition (EMT) involves metastasis and drug resistance; thus, a new EMT reversing agent is required. It has shown that wild-type p53 can reverse EMT back to epithelial characteristics, and iron chelator acting as a p53 inducer has been demonstrated. Moreover, recent study revealed that etoposide could also inhibit EMT. Therefore, combination of etoposide with iron chelator might achieve better inhibition of EMT. To this end, we prepared di-2-pyridineketone hydrazone dithiocarbamate S-propionate podophyllotoxin ester (Ptox(Dpt)) that combined the podophyllotoxin (Ptox) structural unit (etoposide) with the dithiocarbamate unit (iron chelator) through the hybridization strategy. The resulting Ptox(Dpt) inherited characteristics from parent structural units, acting as both the p53 inducer and topoisomerase II inhibitor. In addition, the Ptox(Dpt) exhibited significant inhibition in migration and invasion, which correlated with downregulation of matrix metalloproteinase (MMP). More importantly, Ptox(Dpt) could inhibit EMT in the absence or presence of TGF-beta 1, concomitant to the ROS production, and the additional evidence revealed that Ptox(Dpt) downregulated AKT/mTOR through upregulation of p53, indicating that Ptox(Dpt) induced EMT inhibition through the p53/P13K/AKT/mTOR pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据